Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line chidamide and azacytidine-based combination therapy for TFH-derived peripheral T-cell lymphoma
ChiCTR2100047846Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat, azacitidine, lenalidomide, cyclophosphamide, doxorubicin and 2 more in peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Best overall response rate and 1-year progression-free survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
tucidinostatazacitidinelenalidomidecyclophosphamidedoxorubicin
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on ChiCTR2100047846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047846.